Ramatroban

Ramatroban
Systematic (IUPAC) name
3-((3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl)propanoic acid
Clinical data
Legal status
  • Prescription only
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
IUPHAR ligand
ChemSpider
UNII  Y
ChEMBL
Chemical data
Formula C21H21FN2O4S 
Mol. mass 416.46 g/mol

Ramatroban (INN) is a thromboxane receptor antagonist.[1]

It is also a CRTH2 antagonist.[2]

It is indicated for the treatment of coronary artery disease.[3] It has also been used for the treatment of asthma.[4]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

  1. ^ Sugimoto H, Shichijo M, Iino T et al. (April 2003). "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". J. Pharmacol. Exp. Ther. 305 (1): 347–52. PMID 12649388. doi:10.1124/jpet.102.046748. 
  2. ^ Royer JF, Schratl P, Carrillo JJ et al. (September 2008). "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". Eur. J. Clin. Invest. 38 (9): 663–71. PMID 18837743. doi:10.1111/j.1365-2362.2008.01989.x. 
  3. ^ Fiedler VB, Seuter F, Perzborn E (December 1990). "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease". Stroke 21 (12 Suppl): IV149–51. PMID 2260140. 
  4. ^ Endo S, Akiyama K (November 1996). "[Thromboxane A2 receptor antagonist in asthma therapy]". Nippon Rinsho (in Japanese) 54 (11): 3045–8. PMID 8950952. 

External links

  • (Japanese) Baynas